A Phase 3 clinical trial involving leuprolide has been updated to completed status as of August 14, 2026. The trial, registered as NCT06490328 and titled "Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer," is listed on ClinicalTrials.gov. The study evaluated DKF-MA102 in patients with prostate cancer. Its current status is recorded as COMPLETED. No results, outcomes, or efficacy data are included in this update. The trial phase is designated as Phase 3. This status change reflects only the completion of the trial's conduct as recorded in the registry, not any conclusions about safety or effectiveness. Readers should refer to the official ClinicalTrials.gov listing for further details on the trial design and any future results postings. Leuprolide remains an approved compound, and this update pertains specifically to the DKF-MA102 study population and its associated trial record. For more background on leuprolide, see the compound overview.
Leuprolide Trial DKF-MA102 in Prostate Cancer Marked Completed
See the full leuprolide overview
Source: https://clinicaltrials.gov/study/NCT06490328